

Robert Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135901/publications.pdf>

Version: 2024-02-01

36
papers

15,156
citations

331670

21
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

27976
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) Tj ETQq1.d 0.784334 rgBT		
2	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	5.2	33
3	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Journal of Clinical Oncology, 2022, 40, 1552-1561.	1.6	26
4	Phase II Study of Taselisib in <i>PIK3CA</i> -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precision Oncology, 2022, 6, e2100424.	3.0	9
5	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. JAMA Oncology, 2022, 8, 579.	7.1	27
6	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. Npj Precision Oncology, 2022, 6, 13.	5.4	18
7	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute, 2021, 113, 390-399.	6.3	62
8	Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. Journal of Clinical Oncology, 2021, 39, 557-564.	1.6	69
9	Effect of Capivasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. JAMA Oncology, 2021, 7, 271.	7.1	49
10	Abstract GS4-10: Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer. , 2021, , .		0
11	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. Clinical Cancer Research, 2021, 27, 2996-3004.	7.0	23
12	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. Cancer, 2021, 127, 2545-2552.	4.1	20
13	Reply to K. Ando et al. Journal of Clinical Oncology, 2021, 39, 1947-1948.	1.6	0
14	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. JAMA Oncology, 2020, 6, 367.	7.1	100
15	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Journal of the National Cancer Institute, 2020, 112, 1021-1029.	6.3	138
16	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 2020, 38, 3883-3894.	1.6	168
17	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF^{V600E}</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology, 2020, 38, 3895-3904.	1.6	145
18	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research, 2020, 26, 1812-1819.	7.0	47

#	ARTICLE	IF	CITATIONS
19	Noninferiority trials with nonadherence to the assigned randomized treatment. <i>Clinical Trials</i> , 2019, 16, 673-681.	1.6	1
20	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions. JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
21	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
22	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062.	2.9	2
23	TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. <i>Journal of Clinical Oncology</i> , 2019, 37, 1841-1842.	1.6	5
24	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349
25	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	1.6	505
26	Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1360-1369.	6.3	14
27	Pragmatic approaches to address expansion cohort design. <i>Cancer</i> , 2018, 124, 3290-3292.	4.1	2
28	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
29	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.0	11
30	Estimating Treatment Effect in a Proportional Hazards Model in Randomized Clinical Trials with All-or-Nothing Compliance. <i>Biometrics</i> , 2016, 72, 742-750.	1.4	8
31	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3938-3944.	1.6	223
32	Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. <i>British Journal of Cancer</i> , 2014, 111, 1241-1248.	6.4	37
33	Weighted analyses for cohort sampling designs. <i>Lifetime Data Analysis</i> , 2009, 15, 24-40.	0.9	46
34	Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. <i>Journal of Clinical Oncology</i> , 2007, 25, 2127-2132.	1.6	709
35	Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node-Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189. <i>Journal of Clinical Oncology</i> , 2000, 18, 2059-2069.	1.6	147
36	A Proportional Hazards Model for the Subdistribution of a Competing Risk. <i>Journal of the American Statistical Association</i> , 1999, 94, 496-509.	3.1	10,534